{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:10:35Z","timestamp":1727496635980},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114035","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T03:59:54Z","timestamp":1711511994000},"page":"114035","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Response to Letter RE: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study"],"prefix":"10.1016","volume":"202","author":[{"given":"Pien","family":"Debets","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen M.A.","family":"Dreijerink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Engelsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Dahele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harm R.","family":"Haak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca V.","family":"Steenaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Corssmit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willemien","family":"Menke \u2013 van der Houven van Oordt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114035_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113424","article-title":"Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study","volume":"196","author":"Debets","year":"2024","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2024.114035_bib2","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114035_bib3","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.ejca.2024.114035_bib4","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s10147-021-02021-8","article-title":"Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience","volume":"26","author":"Uchihara","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2024.114035_bib5","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114035_bib6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience","volume":"12","author":"Lagan\u00e0","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ejca.2024.114035_bib7","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-21-1008","article-title":"Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas","volume":"186","author":"Tabarin","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"18","key":"10.1016\/j.ejca.2024.114035_bib8","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3390\/cancers15184491","article-title":"Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic\/Unresectable Adrenocortical Carcinoma with Low Performance Status","volume":"15","author":"Turla","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924006919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924006919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T04:10:14Z","timestamp":1727410214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924006919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":8,"alternative-id":["S0959804924006919"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114035","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to Letter RE: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114035"}}